Feature News

DURHAM, N.C., Jan. 13 /PRNewswire/ -- S&R Communications Group has entered a strategic partnership with Ovation Pharmaceuticals, Inc., to launch Xenazine* (tetrabenazine), a treatment for chorea associated with Huntington's disease (HD). Xenazine is the first and only FDA-approved treatment specifically developed for any HD-related symptom.

"In recent months, the S&R team worked tirelessly to help Ovation launch Xenazine," said S&R President Paul Dreyer. "Having been involved since 2005 in marketing efforts for Xenazine, we know that it is a major advance for those with HD. We are pleased to help Ovation bring this important product to patients, physicians, and caregivers."

Deerfield, Illinois-based Ovation develops, manufactures, and markets therapies to satisfy the unmet needs of patients with severe illnesses. With products available in more than 85 countries, the company is committed to significantly impacting patients' lives through its focus on the central nervous system, hematology/oncology, and hospital-based therapies.

S&R Communications Group is a full-service healthcare marketing and communications company relentlessly pursuing breakthrough creative strategies and programs for its clients. The agency has received numerous awards and other recognition for its work and has earned the respect of its clients in helping them achieve their most ambitious business goals. For more information, visit the award-winning S&R web site at www.srcomgroup.com.

*Xenazine is a registered trademark of Cambridge Laboratories (Ireland) Limited